Identification of Immune-Mediated Causes of Sensorineural Hearing Loss (R21/R33)

Post Date

August 18th 2010

Application Due Date

June 8th 2011

Funding Opportunity Number

RFA-DC-11-002

CFDA Number(s)

93.173

Funding Instrument Type(s)

Grant

Funding Activity Categories

Health

Eligibility Categories

State Governments
Public and State Controlled Institutions of Higher Education
Federally Recognized Native American Tribal Governments
Non-Federally Recognized Native American Tribal Organizations
Non-Profits With 501 (c) (3) Status With The IRS (Except Higher Education Institutions)
Non-Profits Without 501 (c) (3) Status With The IRS (Except Higher Education Institutions)
Private Institutions of Higher Education
For-Profit Organizations (Except Small Businesses)
Small Businesses
Other

Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.

Funding

• Award Range:

  $None - $None

Grant Description

Purpose. The purpose of this FOA is to encourage submission of milestone-driven interdisciplinary Exploratory/Developmental Phased Innovation (R21/R33) research proposals designed to further our understanding of the mechanism, etiology, and pathophysiology of immune mediated sensorineural hearing loss (IMSNHL). Applications considered responsive include studies of 1) ear organ-specific autoimmune sensorineural hearing loss - i.e. autoimmune inner ear disease (AIED), 2) sudden sensorineural hearing loss attributable to AIED, as well as 3) sensorineural hearing loss associated with systemic autoimmune disease. Proposals primarily involving human subjects/tissues will be given highest priority. The human health goal of this FOA is the ultimate translation of the research findings into clinical biomarkers, new diagnostic tests with high sensitivity, specificity and positive predictive value, and the development of therapies that preserve natural hearing. Mechanism of Support. This FOA will utilize the R21/R33 Exploratory/Developmental Phased Innovation grant mechanism. Funds Available and Anticipated Number of Awards. NIDCD has set aside $700K in FY2011 and $1.3M in FY2012 in anticipation of 2-3 awards per application cycle.

Contact Information

• Agency

  Department of Health and Human Services

• Office:

  National Institutes of Health

• Agency Contact:

  NIH OER Webmaster
  FBOWebmaster@OD.NIH.GOV
  

• Agency Mailing Address:

  If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster

• Agency Email Address:

  FBOWebmaster@OD.NIH.GOV

• More Information:

  http://grants.nih.gov/grants/guide/rfa-files/RFA-DC-11-002.html